Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

OBJECTIVES:

- Determine the frequency and prognostic significance of cytogenetic abnormalities in
bone marrow or peripheral blood cells in patients with leukemia prior to treatment and
at various times during treatment undergoing treatment on a companion clinical trial.

- Correlate the presence of cytogenetic features with clinical, pathophysiological,
cellular, and molecular characteristics in these patients.

- Determine the frequency of trisomy 12 in patients with chronic lymphocytic leukemia
(CLL) by fluorescence in situ hybridization (FISH) and conventional cytogenetics.

- Determine the feasibility of FISH as a clinical diagnostic technique in patients with
CLL.

- Correlate clinical-pathological prognostic data with the presence of trisomy 12 as
detected by FISH and cytogenetics in patients with CLL.

- Develop a cooperative group mechanism to study chromosome abnormalities by FISH in
patients with leukemia.

- Provide quality control for all Southwest Oncology Group cytogenetic data.

OUTLINE: Bone marrow and/or peripheral blood samples from patients on specific treatment
protocols for leukemia are analyzed for cytogenetic abnormalities. Samples from patients
with chronic lymphocytic leukemia (CLL) are analyzed for trisomy 12 by fluorescence in situ
hybridization and conventional cytogenetics.

PROJECTED ACCRUAL: Approximately 2,500 patients (1,200 with first-line acute myeloid
leukemia [AML], 500 with first-line acute lymphoblastic leukemia [ALL], 200 with relapsed
AML, 125 with chronic phase chronic myelogenous leukemia [CML], 100 with accelerated phase
or blastic phase CML, 250 with hairy cell leukemia, and 125 with relapsed ALL or CLL) will
be accrued for this study within 5 years.